Table 3.
Association between perioperative factors and adjuvant therapy access
| Variable | Total [n = 317] |
No adjuvant therapy [n = 80] | Adjuvant therapy [n = 237] | p-value |
|---|---|---|---|---|
| Baseline data | ||||
| Age, years [median (IQR)] | 71 (14) | 75 (12) | 70 (12) | <0.001 |
| <60 years | 44 (13.9) | 3 (3.8) | 41 (17.3) | <0.001 |
| −69 years | 98 (13.9) | 18 (22.5) | 80 (33.8) | |
| 70–79 years | 127 (40.1) | 35 (43.8) | 92 (38.8) | |
| ≥80 years | 48 (15.1) | 24 (30) | 24 (10.1) | |
| Sex (male:female) | 155:162 | 44 (55) | 111 (46.8) | 0.245 |
| BMI, kg/m2 [median (IQR)] | 23.7 (3.8) | 23.6 (4.6) | 23.8 (4.8) | 0.906 |
| Underweight – BMI <18.5 | 14 (4.4) | 5 (6.3) | 9 (3.8) | 0.473 |
| Normal – BMI 18.5–25.0 | 184 (58) | 41 (51.9) | 143 (60.3) | |
| Overweight – BMI 25.0–30.0 | 100 (31.5) | 28 (35) | 72 (30.4) | |
| Obese – BMI >30.0 | 19 (6) | 6 (7.5) | 13 (5.5) | |
| Smoking, current or past | 179 (56.5) | 47 (58.7) | 132 (55.3) | 0.742 |
| Alcohol abuse, current or past | 45 (14.2) | 14 (17.5) | 31 (13.1) | 0.328 |
| FH of pancreatic cancer | 33 (10.4) | 9 (11.3) | 24 (10.1) | 0.776 |
| ASA score III–IV | 101 (31.9) | 38 (47.5) | 63 (26.6) | <0.001 |
| CACI [median (IQR)] | 2 (0) | 6 (1) | 5 (2) | <0.001 |
| Weight loss | 192 (60.6) | 50 (62.5) | 142 (59.9) | 0.233 |
| Biliary stenting | 141 (44.5) | 31 (38.7) | 110 (46.4) | 0.683 |
| Cholangitis within 6 weeks from surgery | 20 (6.3) | 4 (5) | 16 (6.8 | 0.233 |
| CA19-9, U/mL [median (IQR)]a | 98 (162) | 115 (230) | 97 (152) | 0.576 |
| Surgical data | 0.417 | |||
| Pancreatoduodenectomy | 199 (62.8) | 49 (61.2) | 150 (63.3) | 0.456 |
| Distal splenopancreatectomy | 96 (30.3) | 23 (28.7) | 73 (30.8) | – |
| Total pancreatectomy | 22 (6.9) | 8 (10) | 14 (5.9) | – |
| Minimally invasive approach | 31 (9.8) | 12 (15) | 19 (8) | 0.069 |
| Vascular resection | 22 (6.9) | 6 (7.5) | 16 (6.8) | 0.820 |
| Estimated blood loss [median (IQR)] | 420 (500) | 460 (473) | 420 (470) | 0.683 |
| Pathological data | ||||
| Stage I | 42 (13.2) | 11 (13.8) | 31 (13.1) | 0.454 |
| Stage II | 110 (34.7) | 32 (40) | 78 (32.9) | – |
| Stage III | 165 (52.1) | 37 (46.2) | 128 (54) | – |
| R status, R1 | 73 (23) | 25 (31.2) | 48 (20.3) | 0.043 |
| N status | ||||
| N0 | 48 (15.1) | 14 (17.5) | 34 (14.3) | 0.760 |
| N1 | 114 (36) | 29 (36.2) | 85 (35.9) | – |
| N2 | 155 (48.9) | 37 (46.2) | 118 (49.8) | – |
Bold values indicate statistically significant
Data are expressed as n (%) unless otherwise specified
CACI Charlson Age Comorbidity Index30, IQR interquartile range, BMI body mass index, FH family history, PH personal history, ASA American Society of Anesthesiologists, CACI Charlson Age Comorbidity Index
aN = 282 (89.9%); in 35 cases, the CA19-9 was not expressed